GPC3 and hepatocellular carcinoma: Currently, there are at least five registered pivotal studies with CAR-T cells targeting glypican 3 (GPC3) or allogenic NK cells for Barcelona C HCC patients (NCT04121273; NCT03198546; NCT02905188; NCT04106167; and NCT03841110).